My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Antares Pharma, Inc. - Common Stock (NQ:ATRS)

N/A UNCHANGED

Last Price Updated: 4:00 PM EDT, May 23, 2022 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Antares Pharma, Inc. - Common Stock

< Previous 1 2 Next >

Looking Into Antares Pharma's Return On Invested Capital ↗

June 08, 2022

Benzinga Pro data, Antares Pharma (NASDAQ:ATRS) reported Q1 sales of $41.56 million. Earnings fell to a loss of $2.32 million, resulting in a 107.1% decrease from last quarter.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For April 14, 2022 ↗

April 14, 2022

Upgrades

Via Benzinga

Antares Pharma's Oral Testosterone Treatment Scores FDA Approval ↗

March 29, 2022

Via Benzinga

Antares Pharma: Q4 Earnings Insights ↗

March 03, 2022

Antares Pharma (NASDAQ:ATRS) reported its Q4 earnings results on Thursday, March 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement....

Via Benzinga

Looking Into Antares Pharma Inc's Recent Short Interest ↗

April 14, 2022

Antares Pharma Inc's (NASDAQ:ATRS) short percent of float has risen 8.8% since its last report. The company recently reported that it has 4.49 million shares sold short, which is...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

April 13, 2022

Gainers

Via Benzinga

Why Is Sierra Oncology (SRRA) Stock Up Today? ↗

April 13, 2022

Late-phase cancer treatment company Sierra Oncology is up big today after being acquired by GlaxoSmithKline. SRRA stock is soaring.

Via InvestorPlace

Why Antares Pharma Stock Is Soaring Today ↗

April 13, 2022

Antares Pharma Inc (NASDAQ: ATRS) shares are trading higher Wednesday after the company announced it will be acquired by Halozyme Therapeutics Inc (NASDAQ: HALO) for $5.60 per share in cash, valuing...

Via Benzinga

Why Is BriaCell (BCTX) Stock Moving Today? ↗

April 13, 2022

BriaCell Therapeutics (BCTX) stock is on the move Wednesday morning after getting Fast Track approval from the FDA for Bria-IMT.

Via InvestorPlace

Why Is Antares Pharma (ATRS) Stock Up Today? ↗

April 13, 2022

Antares Pharma (ATRS) stock is rocketing higher on Wednesday after the company reached an acquisition agreement with Halozyme (HALO).

Via InvestorPlace

Benzinga's Daily Brief On Trending Tickers For April 13, 2022: JPMorgan, PayPal, Bed Bath & Beyond And More ↗

April 13, 2022

Benzinga’s “Daily Brief On Trending Tickers” highlights top-searched tickers from around the web and uses the Benzinga Pro platform to highlight recent news...

Via Benzinga

Biotech Stock Sierra Soars On GSK Buyout As Halozyme Nabs Antares ↗

April 13, 2022

GlaxoSmithKline said Wednesday it will buy Sierra Oncology for $1.9 billion, sending the biotech stock flying.

Via Investor's Business Daily

Futures Rise As Earnings Season Begins ↗

April 13, 2022

On the geopolitical front, the presidents of Poland and the three Baltic states are heading to Kyiv in a show of support that follows the visits of other leaders to the Ukrainian capital, including...

Via Talk Markets

The Daily Biotech Pulse: GlaxoSmithKline And Halozyme Go Shopping, Mylan's Insulin Glargine Recall, Turning Point Shares Lung Cancer Data And More ↗

April 13, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Halozyme Buys Specialty Product Company Antares In $960M Deal

Via Benzinga

Morning Brief: Top Stories Dominating Financial Media on Wednesday, April 13 ↗

April 13, 2022

Reuters Blackrock To Introduce Its First China ETF In 2022: Reuters According to two people with close knowledge of the matter, BlackRock, Inc. (NYSE: BLK) plans to launch...

Via Benzinga

Halozyme Buys Antares In $960M Deal To Create One Drug Delivery, Specialty Product Entity ↗

April 13, 2022

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

April 13, 2022

Rise and shine, trader! Join me today as we break down all the news behind the biggest pre-market stock movers for Wednesday!

Via InvestorPlace

The Daily Biotech Pulse: Sanofi-IGM Ink Antibody Drug Collaboration; NeoGenomics Sinks On CEO Departure, Q1 Warning; Decision Day For Akebia ↗

March 29, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More ↗

March 27, 2022

Biotech stocks reversed course in the week ending March 25, as an increase in risk appetite prompted traders to move money out of defensives and into risky bets.

Via Benzinga

Antares Pharma's Return On Capital Employed Overview ↗

March 08, 2022

According to Benzinga Pro, during Q4, Antares Pharma (NASDAQ:ATRS) earned $32.68 million, a 506.03% increase from the preceding quarter. Antares Pharma also posted a total of $48....

Via Benzinga

The Daily Biotech Pulse: NuCana Shelves Biliary Tract Cancer Study, Tricida Data Readout Pushed Back Due to Ukrainian Crisis, Synlogic Names New CFO ↗

March 03, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus NuCana Discontinues Biliary Tract Cancer Study Following Futility Analysis...

Via Benzinga

Earnings Outlook For Antares Pharma ↗

March 02, 2022

Antares Pharma (NASDAQ:ATRS) is set to give its latest quarterly earnings report on Thursday, 2022-03-03. Here's what investors need to know before the announcement. Analysts...

Via Benzinga

Attention Biotech Investors: Mark Your Calendar For March PDUFA Dates ↗

March 02, 2022

The Food and Drug Administration approval calendar was light in February. Nevertheless, the month saw regulatory nods accorded to some breakthrough therapies. Agios...

Via Benzinga

Earnings Scheduled For March 3, 2022 ↗

March 03, 2022

Companies Reporting Before The Bell • Travelzoo (NASDAQ:TZOO) is expected to report quarterly earnings at $0.13 per share on revenue of $18.23 million. • Urban...

Via Benzinga

FDA Grants Fast Track Tags To Drug Candidates For Antares Pharma, Celcuity, Celularity ↗

January 18, 2022

The FDA has granted Fast Track designation to Antares Pharma Inc's (NASDAQ: ATRS) for ATRS-1902 for adrenal crisis rescue. The development program...

Via Benzinga

5 Value Stocks In The Healthcare Sector ↗

December 20, 2021

What is a Value Stock? A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be...

Via Benzinga

The Daily Biotech Pulse: Calliditas Snags FDA Nod, Novartis to Buy Back $15B In Shares, Valneva Touts Vaccine Data, Immix, Bionomics Debut On Wall Street ↗

December 16, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Calliditas Gets Conditional Approval For Kidney Inflammation Disease Drug...

Via Benzinga

Assertio Shares Gain After Buying Antares' Rheumatoid Arthritis Treatment For $44M ↗

December 16, 2021

Antares Pharma Inc (NASDAQ: ATRS) divested Otrexup (methotrexate) injection to treat rheumatoid arthritis to a subsidiary of Assertio Holdings Inc (NASDAQ: ASRT)...

Via Benzinga

Overview Of Value Stocks In The Healthcare Sector ↗

November 15, 2021

The Meaning Behind Value Stocks A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may...

Via Benzinga

Overview Of Value Stocks In The Healthcare Sector ↗

October 25, 2021

What Defines a Value Stock? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E...

Via Benzinga

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.